Esperion Therapeutics
ESPR
About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Employees: 304
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
37% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
7.68% less ownership
Funds ownership: 57.24% [Q1] → 49.56% (-7.68%) [Q2]
11% less funds holding
Funds holding: 185 [Q1] → 165 (-20) [Q2]
42% less capital invested
Capital invested by funds: $171M [Q1] → $99.3M (-$71.7M) [Q2]
56% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 34
68% less call options, than puts
Call options by funds: $242K | Put options by funds: $768K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
HC Wainwright & Co.
Joseph Pantginis
|
$16
|
Buy
Reiterated
|
17 Jun 2025 |
Financial journalist opinion
Based on 3 articles about ESPR published over the past 30 days
